Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents
- 15 June 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (12) , 5720-5733
Abstract
A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of the title compounds exhibiting potent nanomolar activity in several human cancer cell lines. Of these, compound 22b showed the strongest inhibitory activity against human CEM, MDA-MBA-435, and K562 cells (IC50 = 1 nM), displayed in vitro inhibition of tubulin polymerization (IC50 = 3.93 μM), and significantly induced cell cycle arrest in G2/M phase. In addition, compound 22b could inhibit the tumor growth in colon nude mouse xenograft tumor model significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provided a new molecular scaffold for the further development of antitumor agents that target tubulin.Keywords
This publication has 60 references indexed in Scilit:
- Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulinMedicinal Research Reviews, 2007
- Medicinal Chemistry of Combretastatin A4: Present and Future DirectionsJournal of Medicinal Chemistry, 2006
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Combretastatin A-4 Analogues as Antimitotic Antitumor AgentsCurrent Medicinal Chemistry, 2003
- Structure–activity and crystallographic analysis of benzophenone derivatives—the potential anticancer agentsBioorganic & Medicinal Chemistry Letters, 2003
- Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing AgentsCurrent Pharmaceutical Design, 2002
- Paclitaxel in cancer therapyExpert Opinion on Pharmacotherapy, 2002
- Vinflunine, the latest Vinca alkaloid in clinical developmentCritical Reviews in Oncology/Hematology, 2001
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsPharmacology & Therapeutics, 1991